The Economic and Clinical Impact of Recurring Automated Red Blood Cell Exchange to Manage Sickle Cell Disease in the UK
aRBCX shows potential to improve health outcomes and reduce healthcare costs for individuals with SCD initiating a chronic DMT programme.
Authors
- Stuart Mealing (ORCID: https://orcid.org/0000-0002-2564-1440)
- Matthew Cawson (ORCID: https://orcid.org/0000-0001-7175-0720)
- Isabel Eastwood (ORCID: https://orcid.org/0009-0007-3959-9101)
- Eva Tsouana
- Arne de Kreuk (ORCID: https://orcid.org/0000-0002-9715-9063)
- Martin Besser (ORCID: https://orcid.org/0000-0003-1004-6232)
- Jamie Bainbridge (ORCID: https://orcid.org/0009-0005-0903-3604)
- Anna Yudina
- Sarah M. Medland
Institutions
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Basildon Hospital (GB)
- King's College Hospital (GB)
- University of York (GB)
- Terumo (Germany) (DE)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s41669-025-00605-y
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- King's College Hospital NHS Foundation Trust
- King's College London
- Terumo BCT